Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Arbeitsgemeinschaft medikamentoese Tumortherapie
With
Sanofi
Roche Pharma AG
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented inoperable, locally advanced, metastatic or recurrent NSCLC other than squamous cell
At least 1 measurable lesion according to RECIST criteria
ECOG performance score 0 or 1
Age between 18 and 70 years
You may not be if
Mixed, non-small cell and small cell tumours or mixed adenosquamous carcinomas with a predominant squamous component.
History of haemoptysis
Evidence of tumour invading major blood vessels on imaging.
Previous neoadjuvant/adjuvant chemotherapy.
Previous radiotherapy.
Serious uncontrolled coagulation disorder or thrombo-embolic complications within 6 months prior to study start or history of serious bleeding complications.
Major surgical procedures within 4 weeks prior to study entry.
Minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion.
Non-healing wound, active peptic ulcer or bone fracture.
History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess within 6 months of enrolment.
